Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

Tatsunori Shimoi,1 Akihiko Shimomura,1 Tadahiko Shien,2 Yukari Uemura,3 Hiroaki Kato,4 Masahiro Kitada,5 Tatsuya Toyama,6 Tomohiko Aihara,7 Hirofumi Mukai8 1Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Department of Breast and Endocrine Surgery, Okayama...

Full description

Bibliographic Details
Main Authors: Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, Kitada M, Toyama T, Aihara T, Mukai H
Format: Article
Language:English
Published: Dove Medical Press 2018-02-01
Series:Open Access Journal of Clinical Trials
Subjects:
aromatase inhibitor
estrogen receptor
Online Access:https://www.dovepress.com/open-label-phase-ii-study-of-everolimus-plus-endocrine-therapy-in-post-peer-reviewed-article-OAJCT

Internet

https://www.dovepress.com/open-label-phase-ii-study-of-everolimus-plus-endocrine-therapy-in-post-peer-reviewed-article-OAJCT

Similar Items